A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Gusacitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms RADIANT
- Sponsors Asana BioSciences
- 10 Sep 2019 Status changed from active, no longer recruiting to completed.
- 16 May 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2019 According to an Asana BioSciences media release, outcomes from the trial anticipated in the second half of 2019.